Search
Merck & Co Inc
MRKAdd to Watchlist
128.215USD
-0.115-0.09%
Close 08-06 16:00（ET）Quotes delayed by 15 min
317.28BMarket Cap
35.94P/E TTM
Forecast
Currency: USD Updated: 2026-08-06The current earnings forecast score of Merck & Co Inc is 7.88, ranking 92 out of 156 in the Pharmaceuticals industry. The average price target is 102.50, with a high of 139.00 and a low of 82.00.
Analyst Rating
Based on
32
analysts
Buy
Current Rating
134.131
Target Price
+4.79%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Merck & Co Inc
MRK
32
Amgen Inc
AMGN
37
Biogen Inc
BIIB
37
Eli Lilly and Co
LLY
34
Pfizer Inc
PFE
32
AbbVie Inc
ABBV
32
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Merck & Co Inc's expected revenue for the next quarter?
Merck & Co Inc's expected revenue is 17.30B.
What is Merck & Co Inc's price target?
Analysts forecast that Merck & Co Inc's price target is USD 102.50, with the highest forecast at USD 139.00 and the lowest forecast at USD 82.00.
How have Merck & Co IncMRK's recent earnings per share performed?
The market expectation was USD -0.54, while Merck & Co IncMRK's earnings per share (EPS) for the previous quarter was USD -1.72. EPS for the next quarter is expected at USD 2.22.
What is the analyst rating for Merck & Co Inc?
Based on the ratings of Merck & Co Inc's stock from 32 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.